FOLH1 and prostate carcinoma: For example, the A10 aptamer, which targets the prostate-specific membrane antigen (PSMA), has been widely used to functionalize nanoparticles for delivering chemotherapy to prostate cancer cells, showing significantly enhanced efficacy in preclinical models (Figure 2) [48].